A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Natera, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 40,502 shares of NTRA stock, worth $5.09 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
40,502
Holding current value
$5.09 Million
% of portfolio
0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$85.28 - $112.6 $3.45 Million - $4.56 Million
40,502 New
40,502 $4.39 Million
Q4 2023

Feb 14, 2024

BUY
$37.55 - $62.64 $2.65 Million - $4.41 Million
70,459 New
70,459 $4.41 Million
Q2 2023

Aug 14, 2023

BUY
$47.08 - $55.16 $758,788 - $889,013
16,117 New
16,117 $784,000
Q4 2022

Feb 14, 2023

BUY
$34.17 - $47.91 $942,852 - $1.32 Million
27,593 Added 62.42%
71,799 $2.88 Million
Q3 2022

Nov 14, 2022

BUY
$36.93 - $56.68 $1.63 Million - $2.51 Million
44,206 New
44,206 $1.94 Million
Q2 2022

Aug 15, 2022

SELL
$28.13 - $44.54 $805,671 - $1.28 Million
-28,641 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$30.32 - $91.33 $868,395 - $2.62 Million
28,641 New
28,641 $1.17 Million
Q4 2021

Feb 14, 2022

SELL
$86.26 - $119.0 $167,171 - $230,622
-1,938 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$100.17 - $126.36 $9.45 Million - $11.9 Million
-94,312 Reduced 97.99%
1,938 $216,000
Q2 2021

Aug 16, 2021

BUY
$86.05 - $119.72 $6.63 Million - $9.22 Million
77,010 Added 400.26%
96,250 $10.9 Million
Q1 2021

May 17, 2021

SELL
$91.47 - $124.36 $2.78 Million - $3.78 Million
-30,380 Reduced 61.23%
19,240 $1.95 Million
Q4 2020

Feb 16, 2021

BUY
$66.66 - $111.74 $1.86 Million - $3.11 Million
27,834 Added 127.76%
49,620 $4.94 Million
Q3 2020

Nov 16, 2020

BUY
$45.89 - $72.67 $999,759 - $1.58 Million
21,786 New
21,786 $1.57 Million

Others Institutions Holding NTRA

About Natera, Inc.


  • Ticker NTRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 96,957,400
  • Market Cap $12.2B
  • Description
  • Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify sing...
More about NTRA
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.